摘要 |
<p>Peptides selected from peptides having 1st to 20th, 1st to 29th, or 17th to 28th amino acid sequence in the formula [I]: Ala-Asp-Ser-Asn-Pro-Arg-Gly-Val-Ser-Ala-Tyr-Leu-Ser-Arg-Pro-Ser-Pro-Ph e-Asp-Leu- Phe-Ile-Arg-Lys-Ser-Pro-Thr-Ile-Thr and peptides having 1st to 21st, 3rd to 47th, 10th to 17th, 10th to 24th, 22nd to 40th, 38th to 50th, 39th to 45th, 40th to 45th, or 40th to 54th amino acid sequence in the formula [II]: Gln- X -Arg-Val-Thr-His-Pro-His-Leu-Pro-Arg-Ala-Leu-Met-Arg-Ser-Thr-Thr-Lys-T hr-R> Ser-Gly-Pro-Arg-Ala-Ala-Pro-Glu-Val-Tyr-Ala-Phe-Ala-Thr-Pro-Glu-Trp-Pr o-Gly-Ser- Arg-Asp-Lys-Arg-Thr-Leu-Ala- X -Leu-Ile-Gln-Asn-Phe-Met wherein X is Cys or Ser, and partially modified peptides at an amino acid residue thereof, and salts thereof, have excellent anti-allergic activity and are useful for the prophylaxis and treatment of allergic diseases.</p> |
申请人 |
DAINIPPON PHARMACEUTICAL CO., LTD.;AJINOMOTO CO., INC. |
发明人 |
NAKAMURA, HIDEO;ISHII, KATSUMI;ARIYOSHI, YASUO;NIO, NORIKI |